LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Vanda Pharmaceuticals Inc

Fermé

4.78 -0.83

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.75

Max

4.94

Chiffres clés

By Trading Economics

Revenu

-25M

-29M

Ventes

-3.1M

50M

BPA

-0.5

Marge bénéficiaire

-58.94

Employés

368

EBITDA

-23M

-31M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+242.32% upside

Dividendes

By Dow Jones

Prochains Résultats

30 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-4.2M

263M

Ouverture précédente

5.61

Clôture précédente

4.78

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Vanda Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 juin 2025, 20:51 UTC

Résultats

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 juin 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 juin 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 juin 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 juin 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 juin 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 juin 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 juin 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 juin 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 juin 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 juin 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 juin 2025, 18:39 UTC

Market Talk
Résultats

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 juin 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 juin 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 juin 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 juin 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 juin 2025, 17:08 UTC

Résultats

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 juin 2025, 16:52 UTC

Acquisitions, Fusions, Rachats

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 juin 2025, 16:22 UTC

Résultats

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 juin 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27 juin 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 juin 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27 juin 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27 juin 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 juin 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparaison

Variation de prix

Vanda Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

242.32% hausse

Prévisions sur 12 Mois

Moyen 16.5 USD  242.32%

Haut 20 USD

Bas 13 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

4.22 / 4.44Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.